Article type: Mini Review

Home Page URL: https://www.alliedacademies.org/gastroenterology-and-digestive-diseases/

Targeting the tumor microenvironment in pancreatic cancer: New avenues for immunotherapy.

Hiroyuki Satoi*

Department of Surgery, University of Colorado School of Medicine, USA

***Correspondence to:** Hiroyuki Satoi, Department of Surgery, University of Colorado School of Medicine, Aurora, CO, USA, E-mail: hiroyuki.sat@cuanschutz.edu

Received: *01-Apr-2025, Manuscript No. JGDD-25-167176;* ***Editor assigned:*** *02-Apr-2025, Pre QC No. JGDD-25-167176 (PQ);* ***Reviewed:*** *15-Apr-2025, QC No. JGDD-25-167176;* ***Revised:*** *19-Apr-2025, Manuscript No. JGDD-25-167176 (R);* ***Published:*** *26-Apr-2025, DOI: 10.35841/JGDD-10.2.257*

Introduction

Pancreatic cancer, particularly Pancreatic Ductal Adenocarcinoma (PDAC), remains one of the most lethal malignancies, with a 5-year survival rate below 10%. One of the main obstacles to effective treatment is its complex and immunosuppressive Tumor Microenvironment (TME), which not only supports tumor growth but also limits the efficacy of current therapies including immunotherapy.Unlike cancers such as melanoma or non-small cell lung cancer that respond to immune checkpoint blockade, pancreatic cancer has proven resistant to such approaches. Recent research suggests that the failure of immunotherapy in PDAC is due more to the TME than the tumor cells themselves. Therefore, reprogramming or disrupting the TME represents a promising strategy to unlock immunotherapeutic potential in pancreatic cancer [1].

This article explores the key components of the pancreatic cancer microenvironment, their role in immune evasion, and emerging strategies to remodel this space for effective immunotherapy.The pancreatic TME is characterized by a dense desmoplastic stroma, abundant immunosuppressive cells, poor vascularization, and a low mutational burden all of which contribute to immune escape and treatment resistance.CAFs produce Extracellular Matrix (ECM) proteins, creating a physical barrier to immune cell infiltration.They secrete TGF-β and CXCL12, which suppress T-cell activation and attract immunosuppressive cell types [2].

Skewed toward the M2 phenotype, TAMs release IL-10 and arginase-1, blunting cytotoxic T-cell responses. TAMs also promote angiogenesis and metastasis. MDSCs accumulate in the TME and inhibit T-cell proliferation. They metabolize L-arginine and L-cysteine, depriving effector T cells of nutrients essential for their function.Highly enriched in the PDAC TME, Tregs suppress anti-tumor immunity through CTLA-4 signaling and cytokine release (e.g., IL-10, TGF-β).Given the role of the microenvironment in immune suppression, combining immunotherapy with TME-modifying agents is showing promise in preclinical and early clinical trials [3].

PEGPH20, a pegylated hyaluronidase, degrades hyaluronic acid to improve drug and immune cell penetration. FAK inhibitors target focal adhesion kinase pathways in stromal cells, enhancing T-cell infiltration.CSF1R inhibitors block macrophage recruitment and shift the TAM phenotype from M2 to M1 (pro-inflammatory). CD40 agonists activate antigen-presenting cells and promote immune-mediated tumor clearance.Alone, PD-1/PD-L1 inhibitors have little effect in PDAC, but when combined with stroma-targeting agents, they show synergistic responses.Trials are exploring nivolumab + CAF-targeting therapy and atezolizumab + MEK inhibitors [4].

GVAX and algenpantucel-L are vaccine-based strategies that attempt to convert the tumor into an "in situ" vaccine. Oncolytic viruses such as pelareorep are designed to infect and kill tumor cells while stimulating a localized immune response.A combination of CD40 agonist, chemotherapy, and checkpoint blockade showed improved T-cell infiltration and durable responses in some patients.Evaluating CSF1R blockade with anti-PD-1 therapy to overcome macrophage-mediated resistance.Testing PEGPH20 with

Citation: Satoi H. Targeting the tumor microenvironment in pancreatic cancer: New avenues for immunotherapy. J Gastroenterology Dig Dis. 2025;10(2):257

nivolumab in patients with high-stroma PDAC. Although outcomes are early and sample sizes small, these trials point toward modifying the TME as essential for unlocking immunotherapy efficacy in PDAC.Not all PDAC tumors have the same stromal or immune profiles. BioAprker-driven selection (e.g., stromal density, TIL presence) may enhance trial outcomes.Combining TME-targeting and immune therapies increases the risk of immune-related Adverse Events (irAEs), requiring careful monitoring [5].

Conclusion

Pancreatic cancer's resistance to immunotherapy stems not from an inherent lack of immunogenicity, but from a highly suppressive and structured tumor microenvironment. Emerging strategies that target stromal barriers, reprogram immune-suppressive cells, and prime tumors for immune attack represent exciting new avenues in the fight against PDAC. By combining these TME-modulating approaches with immunotherapy, we inch closer to turning cold tumors into hot ones, potentially transforming pancreatic cancer into a more treatable condition. Continued research, robust clinical trials.

References

1. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. Jama. 2011;305(19):1969-77.
2. Cheung TK, Wong BC, Lam SK. Gastro-Oesophageal reflux disease in Asia. Drugs. 2008;68(4):399-406.
3. Cho YS, Choi MG, Jeong JJ, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Asan-si, Korea. Am J Gastroenterol. 2005;100(4):747-53.
4. Dent J, El-Serag HB, Wallander M, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54(5):710-7.
5. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 2005;100(1):190-200

Citation: Satoi H. Targeting the tumor microenvironment in pancreatic cancer: New avenues for immunotherapy. J Gastroenterology Dig Dis. 2025;10(2):257